BrincidofovirFanconi syndrome and worsening renal function following off-label therapy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1838卷 / 1期

关键词：

D O I：

10.1007/s40278-021-89435-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：116 / 116

相关论文

共 50 条

[1] ModafinilMuscular pain worsening following off-label use: case report
Reactions Weekly, 2022, 1925 (1) : 323 - 323
[2] BevacizumabProteinuria and worsening of hypertension following an off-label use: case report
Reactions Weekly, 2022, 1916 (1) : 104 - 104
[3] RituximabInfection following an off-label therapy: case report
Reactions Weekly, 2017, 1642 (1) : 268 - 268
[4] OlaparibAnaemia following off-label therapy: case report
Reactions Weekly, 2020, 1813 (1) : 183 - 183
[5] Ipilimumab/nivolumabVitiligo and worsening of hypothyroidism following off-label use: case report
Reactions Weekly, 2021, 1886 (1) : 238 - 238
[6] SorafenibDRESS syndrome following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 420 - 420
[7] MizoribineFanconi syndrome following off-label treatment: case report
Reactions Weekly, 2021, 1838 (1) : 341 - 341
[8] ModafinilDRESS syndrome following off-label use: case report
Reactions Weekly, 2022, 1925 (1) : 322 - 322
[9] BupivacaineCompartment syndrome following an off-label use: case report
Reactions Weekly, 2017, 1644 (1) : 61 - 61
[10] BrexpiprazolePisa Syndrome following off-label use: case report
Reactions Weekly, 2022, 1910 (1) : 118 - 118

← 1 2 3 4 5 →